Reported 28 days ago
Pfizer's stock fell over 1% on Tuesday despite reporting strong third-quarter earnings with a 32% revenue increase year-over-year, driven largely by its Covid products. CEO Albert Bourla's comments addressing criticism from activist investor Starboard Value regarding recent acquisitions overshadowed the positive results, leading to a cautious market response even as Pfizer raised its 2024 revenue and profit forecasts.
Source: YAHOO